Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of five clinical trials

Jordan Berlin,E. Van Cutsem,Marc Peeters,J.R. Hecht,R. Ruiz,Michael S. Wolf,R Amado,N. J. Meropol

Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of five clinical trials

2007

Jordan Berlin
E. Van Cutsem
Marc Peeters
J.R. Hecht
R. Ruiz
Michael S. Wolf
R Amado
N. J. Meropol

4134 Background: Panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), is approved for EGFr-expressing mCRC patients (pts) with disease progression (PD...

Keywords:

Clinical trial
Pathology
Skin toxicity
Colorectal cancer
Medicine
Panitumumab
Oncology
Internal medicine
predictive value
Epidermal growth factor receptor
Monoclonal antibody
pooled analysis
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations